Navrogen
is a Pennsylvania-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read moreNavrogen
is a Pennsylvania-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cancer... Read more
President & CEO
Nicholas C. Nicolaides
News
Jul 07, 2026
EIN Presswire
Press Release: Navrogen : Navrogen Publishes Breakthrough on NAV-005, A CA125 Antagonist That Improves Antibody Cancer Therapy and ADC Efficacy
Jan 20, 2026
EIN Presswire
Press Release: Navrogen : Navrogen Granted Composition and Use Patent to Humoral Immuno-Oncology Factor Antagonist NAV-005 to Treat Cancer
Oct 30, 2025
EIN Presswire
Press Release: Navrogen : Navrogen Granted Patents on Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate
May 05, 2025
EIN Presswire
Press Release: Navrogen : Navrogen Announces Publication on the CA125-Refractory NAV-006 Ab Treatment of Immunosuppressed Follicular Lymphoma
Mar 26, 2025
EIN Presswire
Press Release: Navrogen : Navrogen Announces Publication and Presentation at the AACR Annual Meeting of a Novel Antibody Engineering Platform
Apr 04, 2024
StreetInsider
Press Release: Navrogen : Navrogen Presents Its Anti-CD20 Antibody NAV-006 and ICAM-1 Refractory Antibody-Drug Conjugate Platform at the 2024 American Association for Cancer Research Annual Meeting
May 18, 2023
StreetInsider
Press Release: Navrogen : Navrogen Announces Publication of NAV-001 Antibody-Drug Conjugate Development and Efficacy in Humoral Immunosuppressed Cancers
Apr 12, 2023
PR Newswire
Press Release: Navrogen : Navrogen Presents Preclinical Data on NAV-001 Antibody-Drug Conjugate and NAV-003 Bispecific Programs at the 2023 American Association for Cancer Research Annual Meeting
Mar 27, 2023
EIN Presswire
Press Release: Navrogen : Navrogen and National Cancer Institute Establish Collaboration Study Impact Immunosuppressive Factor CA125 on Rituximab
Nov 08, 2022
Pharmaceutical Business Review
Navrogen: Navrogen signs agreement with US NCI for NAV-001 development
Navrogen Competitors
1
2
3
4
5
6
7
8
9